# MAIA Biotechnology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/MAIA Biotechnology, Inc.). ## Overview MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with its lead molecule ateganosine (formerly THIO) at the center of its pipeline. The company is based in Chicago and operates through U.S. and international subsidiaries that support preclinical and clinical development activities. ## Products & services • Ategamosine (THIO) oncology drug candidate • THIO-101 clinical program • THIO-102 clinical program • THIO-103 clinical program • THIO-104 clinical program • Preclinical and clinical development services for pipeline assets - **Lead oncology candidate** (0%) — Ategamosine (THIO) and related clinical trial programs aimed at treating cancer. - **Clinical development programs** (0%) — Ongoing human trials and supporting development work for the THIO platform. - **Preclinical development** (0%) — Laboratory and early-stage work conducted through U.S., Australian, and Romanian operations. - **Pipeline expansion** (0%) — Acquisition or in-licensing of additional product candidates to broaden the portfolio. - Ategamosine (THIO), the company’s lead cancer drug candidate - THIO-101, THIO-102, THIO-103 and THIO-104 clinical trial programs - Targeted immunotherapy development for oncology indications - Preclinical and clinical development activities through subsidiaries - Pipeline expansion via acquisition or in-licensing of products ## Customers MAIA does not currently sell commercial products; its primary “customers” are clinical investigators, trial sites, and ultimately patients enrolled in oncology studies. In a broader business sense, future customers would be oncology physicians, hospitals, and healthcare systems if ateganosine or other pipeline assets are successfully approved and commercialized. - **Clinical trial participants** (primary) — Patients enrolled in oncology studies who receive ateganosine in MAIA-sponsored trials. - **Clinical investigators and trial sites** (primary) — Hospitals, research centers, and investigators that execute the company’s clinical programs. - **Future oncology prescribers** (secondary) — Oncologists and healthcare systems that could adopt the drug if it reaches approval. - **Potential licensing partners** (secondary) — Biopharma partners that may collaborate on development, commercialization, or asset in-licensing. - Clinical trial sites that run MAIA-sponsored oncology studies - Patients enrolled in THIO/ateganosine clinical programs - Oncology physicians and hospitals as future adopters - Potential licensing or development partners for pipeline assets - Investors and capital providers funding development ## Geography MAIA is headquartered in Chicago, Illinois, and its operations are primarily U.S.-based, with team members also working remotely from California, North Carolina, and New Jersey. The company has wholly owned subsidiaries in Australia and Romania to support preclinical and clinical development, which broadens its operational footprint beyond the United States. - Headquartered in Chicago, Illinois - U.S. team members also work remotely in several states - Australian subsidiary supports preclinical and clinical work - Romanian subsidiary supports preclinical and clinical work - No disclosed revenue geography because the company has no revenue ## Strategy MAIA’s strategy is centered on advancing ateganosine through clinical development while preserving flexibility to fund operations through equity, debt, or other financings. The company is also seeking to broaden its pipeline through acquisition or in-licensing, while managing cash carefully because it currently has no revenue and substantial going-concern pressure. - **Advance ateganosine clinical development** (short-term) — The lead asset is the core value driver and the main path to future commercialization. - **Secure additional financing** (short-term) — The company has no revenue and needs capital to fund trials and operations. - **Broaden the pipeline** (medium-term) — Additional assets could reduce single-asset dependence and improve long-term optionality. - Advance ateganosine through ongoing clinical trials - Use subsidiaries to support preclinical and clinical execution - Raise capital through equity and debt financings - Control expenses to extend cash runway - Expand the pipeline via acquisition or in-licensing ## Risks MAIA is a development-stage company with no revenue, so its business depends on successful clinical execution and continued access to capital. The company also faces going-concern risk, listing compliance risk, and the usual biotech uncertainty around trial outcomes, regulatory approval, and commercialization timing. - **Going-concern and liquidity risk** [high] — The company has no revenue, negative operating cash flow, and needs external financing to continue. - **Clinical development failure** [critical] — Ategamosine is the lead asset, so adverse trial results would materially impair prospects. - **Capital market dependence** [high] — Operations are funded through equity issuances and private placements, which may be dilutive. - **Listing compliance risk** [medium] — Failure to meet NYSE American requirements could trigger delisting and reduce trading liquidity. - **Geographic execution risk** [medium] — Clinical and preclinical work spans the U.S., Australia, and Romania, increasing coordination complexity. - No revenue and ongoing operating losses increase financing dependence - Clinical trial failure could eliminate the lead asset’s value - Going-concern uncertainty if capital cannot be raised - NYSE American listing compliance risk could hurt liquidity - Single-asset concentration increases execution and valuation risk ## Accounting The most important accounting issue is going-concern assessment, because management states that substantial doubt exists about the company’s ability to continue without additional financing. Investors should also watch equity issuance accounting, warrant liability remeasurement, and stock-based compensation, all of which can materially affect reported losses and cash flow presentation. - **Going-concern evaluation** — Affects financial statement presentation and investor assessment of liquidity - **Warrant liability fair value remeasurement** — Can materially swing quarterly net loss - **Stock-based compensation** — Inflates reported G&A and net loss - **Equity financing costs** — Impacts cash runway and financing efficiency - Going-concern assessment reflects dependence on future financing - Warrant liability remeasurement can create non-cash earnings volatility - Stock-based compensation affects reported operating losses - Equity issuance costs reduce net financing proceeds - No revenue yet, so expense recognition drives results --- *Last updated: 2026-04-28T20:23:57.792334+00:00*